LRP2 (rs2302694) mutations were detected in a range of cancers, with melanoma (28.18%), uterine sarcoma (17.99%), and lung squamous cell carcinoma (16.32%) with the highest mutation rates (24). This evidence concerns the gene LRP2 and cancer.